Worth reading
64In focus
Scored from 5 of 6 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
-10.6
Year-on-year change in revenue (%)Wording
Avoiding a definitive answer
How definitive the wording is.Results for this period
Full year2023年4月1日〜2024年3月31日Non-consolidated (standalone)Japanese GAAPNet Sales7,738¥ millionYear on year -10.6%
Operating profit-195¥ million
Ordinary income-161¥ million
Net income attributable to owners of the parent108¥ millionYear on year -21.2%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Net income per share3円13銭
Operating Margin-2.5%
Financial position at period-end
Total assets15,421¥ million
of which net assets 12,026 ¥ millionEquity ratio 78.0%vs. prior year-end +2.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-107
Investment-2
Financials-104
Net change-213
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥3,664 million
Segment revenuePharmaceuticals ¥3,393,447 thousand (YoY -23.9%), Healthcare Business ¥2,452,690 thousand (YoY +22.5%), Global Business ¥1,718,102 thousand (YoY -14.9%), Real estate leasing ¥174,185 thousand (YoY -3.4%)
Segment profitPharmaceuticals ¥-777,602 thousand, Healthcare Business ¥430,896 thousand, Global Business ¥93,531 thousand, Real estate leasing ¥57,662 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net SalesUndecided
Operating profitUndecided
Ordinary incomeUndecided
Net incomeUndecided
Annual Dividend Forecast¥3 → Undecided
Payout ratio96.0%
Shareholder Return Policy安定的な配当の実施、配当性向50％以上を基本とする
Factors Behind Changes in Business Performance
医薬事業では「マキュエイド眼注用40㎎」の供給停止、薬価引き下げ、花粉飛散状況などにより売上が減少。ヘルスケア事業では広告宣伝費の抑制により一部製品が減収となった一方、「強力わかもと」は増収。グローバル事業では輸出用「強力わかもと」や国内点眼薬受託製品が減収。不動産賃貸業ではテナント入替の影響で賃貸料が減少。
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Material subsequent events2024年4月26日開催の取締役会で、「強力わかもと」の生産能力向上を目的とする現行ライン改造・新規設備導入を決議。工事期間は2024年〜2027年予定、投資予定額は約20億円。
Impairment lossNot applicable for the fiscal year
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities ¥366,278 thousand / Extraordinary loss Loss on disposal of non-current assets ¥5,428 thousand, Loss on disposal of inventories ¥40,137 thousand
Depreciation and amortization¥411,587 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingAvailable (participants not specified)
Issued Shares at Period-End34,838,325 shares
Treasury Shares at Period-End131,605株
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 2023年4月1日〜2024年3月31日 |
| Net Sales | ¥7,738 million (YoY -10.6%) |
| Operating profit | ¥-195 million |
| Ordinary income | ¥-161 million |
| Profit attributable to owners of the parent | ¥108 million (YoY -21.2%) |
| Net income per share | 3円13銭 |
| Operating Margin | -2.5% |
| Equity ratio | End of the current fiscal period 78.0% / End of previous period 75.8% |
| Total assets | ¥15,421 million |
| Net assets | ¥12,026 million |
| Cash flows from operating activities | ¥-107 million |
| Cash flows from investing activities | ¥-2 million |
| Cash flows from financing activities | ¥-104 million |
| Cash and cash equivalents at end of period | ¥3,664 million |
| Full-year earnings forecast | Net Sales Undecided / Operating profit Undecided / Ordinary income Undecided / Net income Undecided |
| Annual Dividend Forecast | ¥3 → Undecided |
| Payout ratio | 96.0% |
| Shareholder Return Policy | 安定的な配当の実施、配当性向50％以上を基本とする |
| Segment revenue | Pharmaceuticals ¥3,393,447 thousand (YoY -23.9%), Healthcare Business ¥2,452,690 thousand (YoY +22.5%), Global Business ¥1,718,102 thousand (YoY -14.9%), Real estate leasing ¥174,185 thousand (YoY -3.4%) |
| Segment profit | Pharmaceuticals ¥-777,602 thousand, Healthcare Business ¥430,896 thousand, Global Business ¥93,531 thousand, Real estate leasing ¥57,662 thousand |
| Depreciation and amortization | ¥411,587 thousand |
| Impairment loss | Not applicable for the fiscal year |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities ¥366,278 thousand / Extraordinary loss Loss on disposal of non-current assets ¥5,428 thousand, Loss on disposal of inventories ¥40,137 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | 2024年4月26日開催の取締役会で、「強力わかもと」の生産能力向上を目的とする現行ライン改造・新規設備導入を決議。工事期間は2024年〜2027年予定、投資予定額は約20億円。 |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Available (participants not specified) |
| Issued Shares at Period-End | 34,838,325 shares |
| Treasury Shares at Period-End | 131,605株 |
| Factors Behind Changes in Business Performance | 医薬事業では「マキュエイド眼注用40㎎」の供給停止、薬価引き下げ、花粉飛散状況などにより売上が減少。ヘルスケア事業では広告宣伝費の抑制により一部製品が減収となった一方、「強力わかもと」は増収。グローバル事業では輸出用「強力わかもと」や国内点眼薬受託製品が減収。不動産賃貸業ではテナント入替の影響で賃貸料が減少。 |
Items this document does not state (4)
Revision to Earnings ForecastRegional salesOrders received and order backlogChanges in the scope of consolidation
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.医薬事業では「マキュエイド眼注用40㎎」の供給停止、薬価引き下げ、花粉飛散状況の影響などで売上が減少した。ヘルスケア事業では広告宣伝費の抑制により一部製品の売上が減少し、次期予想については「マキュエイド眼注用40㎎」の出荷再開時期と影響額が未確定であることを理由としている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.